Hunan Fangsheng Pharmaceutical (603998.SH): The clinical trial of Rulogoli tablets has been approved.
Fangsheng Pharmaceutical (603998.SH) announced that its wholly-owned subsidiary, Guangdong Fangsheng Jianmeng Pharmaceutical Co., Ltd. (referred to as "...
Hunan Fangsheng Pharmaceutical (603998.SH) announced that its wholly-owned subsidiary Guangdong Fangsheng Jianmeng Pharmaceutical Co., Ltd. (referred to as "Fangsheng Jianmeng") received approval from the National Medical Products Administration for the research and development project of Rilugolix tablets, a chemical generic drug. The approval allows the product to conduct clinical trials for prostate cancer.
Related Articles
US Stock Market Move | Popular Chinese concept stocks collectively rose sharply, with New Oriental Education & Technology Group, Inc. Sponsored ADR (EDU.US) jumping more than 8%.
US Stock Market Move | Gold stock continues to strengthen, Kinross Gold Corporation (KGC.US) rises more than 7%
US Stock Market Move | Omeros Corporation (OMER.US) soars 150% following asset purchase and license agreement with Novo Nordisk A/S Sponsored ADR Class B.
US Stock Market Move | Popular Chinese concept stocks collectively rose sharply, with New Oriental Education & Technology Group, Inc. Sponsored ADR (EDU.US) jumping more than 8%.
US Stock Market Move | Gold stock continues to strengthen, Kinross Gold Corporation (KGC.US) rises more than 7%
US Stock Market Move | Omeros Corporation (OMER.US) soars 150% following asset purchase and license agreement with Novo Nordisk A/S Sponsored ADR Class B.
